BioSpace News Archive

HilleVax, Inc. announced that it will present at the 2023 Cantor Global Healthcare Conference in New York, New York on Thursday, September 28, 2023 at 12:40 p.m. EST.

Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL) today announced that the first patient has been dosed in a Phase 1b/2 clinical trial evaluating its lead candidate, GC012F, in patients with relapsed or refractory multiple myeloma (RRMM) in the United States. GC012F is the Company’s autologous therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19, developed on the proprietary FasTCAR next-day manufacturing platform.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced initial aflibercept protein expression data from its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD).

GENFIT announced the publication of data demonstrating the effectiveness of its non-alcoholic steatohepatitis diagnostic technology NIS4® by the FNIH’s NIMBLE project in the scientific journal, Nature Medicine.

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2023.

Applied BioMath (www.appliedbiomath.com) today announced the full speaker lineup for their Quantitative Systems Pharmacology (QSP) Summit occurring Thursday, October 12, 2023 in Cambridge, MA.

Danaher Corporation announced that it will webcast its quarterly earnings conference call for the third quarter 2023 on Tuesday, October 24, 2023 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

Pacira BioSciences, Inc., the industry leader in its commitment to non-opioid pain management and regenerative health solutions, announced that David Stack will retire from his role as Chairman and Chief Executive Officer.

Cytovance Biologics, a leading full-service mammalian and microbial large molecule contract development and manufacturing organization (CDMO), announced today the addition of Axel Schleyer, Ph.D., MBA,

MDxHealth SA (NASDAQ/Euronext: MDXH), a leading commercial-stage precision diagnostics company, today announced a research collaboration with the University of Oxford to investigate the correlation between the Genomic Prostate Score (GPS) test and prostate cancer progression following treatment for localized prostate cancer.